Kornimate/medical-research-clean huggingface dataset:
short term topical tetracaine is safe and highly efficacious for the treatment of pain caused by corneal abrasions

Conditions: Corneal Abrasion

Summary: the objective of this study was to show that patients with corneal abrasions would experience more pain relief with short term topical tetracaine than placebo, have similar complication rates, and take less hydrocodone for breakthrough pain.

corneal abrasions are among the most common eye-related injuries seen in the emergency department (ed). topical anesthetic drops are routinely used prior to slit-lamp examination for diagnosis of corneal abrasions and often provide immediate pain relief. patients are then sent home with oral analgesics and topical antibiotics. the use of topical anesthetics for outpatient treatment of corneal abrasions is discouraged by most emergency medicine textbooks due to concerns over safety. case reports of abuse and misuse as well as animal studies have suggested that long term use of topical anesthetics may lead to rare complications. two clinical trials showed no delayed healing after a short course of topical anesthetics following prk surgery. whether this could be applied to nonsurgical patients in the ed was investigated by two small clinical trials that showed similar efficacy and safety but were underpowered to prove a statistical difference. in 2014, a larger randomized trial demonstrated the safety of tetracaine for ed patients with corneal abrasions but failed to show a significant difference in patient visual analogue scale (vas) pain ratings over time. more recently, a retrospective cohort study of 444 ed patients given tetracaine for 24 hours reported no serious complications or uncommon adverse events. if topical anesthetics could be safely prescribed for short term use in the management of corneal abrasions, it is possible that this would decrease use of systemic opioids for this purpose. the aim of this randomized, double-blind trial was to compare the effectiveness of topical tetracaine versus placebo in ed patients with corneal abrasions as measured by a reduction in the vas score.

Eligibility criteria:
inclusion criteria: * all patients aged 18 years to 80 years old presenting to the ed with suspected acute corneal abrasion from mechanical trauma or removal of a foreign body by the physician were included exclusion criteria: * patients were excluded if they wore contact lenses, had previous corneal surgery or transplant in the affected eye, presented more than 36 hours after their injury, had a grossly contaminated foreign body or coexisting ocular infection. additional exclusion criteria were pregnancy, retained foreign body, penetrating eye injury, immunosuppression, allergy to study medication, inability to attend follow up, inability to fluently read and speak english or spanish, or any injury requiring urgent ophthalmologic evaluation (large or complicated abrasions with significant vision loss, corneal ulcers, corneal lacerations).
textbook outcomes of emergency cholecystectomies in elderly patients

Conditions: Acute Cholecystitis

Summary: textbook outcome is a measure used to assess the quality of surgical practice. the goal of this observational study is to compare textbook outcomes of elderly patients (≥65 years) in emergency cholecystectomies with younger patients(\&lt;65 years ) via using aforementioned criteria

textbook outcome is a measure used to assess the quality of surgical practice and has been implemented in various areas of surgical literature. it is defined as an uneventful operative and postoperative period that leads to successful surgery without negative outcomes. there is still no consensus on the textbook outcome concept for emergency cholecystectomy. sprimacc collaborative study has presented and offered a list of textbook outcome criteria. their proposal was: no 30-day mortality, no 30-day postoperative complications (any cd≥i is considered non-to), no readmission within 30 days, and hospital stay≤7 days (75th percentile) and full laparoscopic surgery. the goal of this observational study is to compare textbook outcomes of elderly patients (≥65 years) in emergency cholecystectomies with younger patients(\&lt;65 years ) via using aforementioned criteria

Eligibility criteria:
inclusion criteria: * all patients underwent emergency cholecystectomy with a diagnosis of acute choleystitis exclusion criteria: * patients underwent open surgery directly. patients diagnosed as malignant postoperatively in the pathology report

Keywords: acute cholecystitis textbook outcome emergency surgery
a feasibility study to evaluate the tolerability of oph1 compared to restasis in healthy volunteers

Conditions: Dry Eye Syndromes

Summary: 20 healthy participants will be evaluated for tolerability and safety of a new eye drop formulation for treatment of dry eye syndromes, oph1 0.5% cyclosporine a (csa) compared with restasis 0.05% csa ophthalmic formulation.

20 healthy participants will be enrolled to the study and randomized into two groups of 10 participants each. in one group participants will be treated with oph1 0.5% csa ophthalmic formulation and in the other group with restasis 0.05% csa ophthalmic formulation. both groups will be treated with the eye drops in the right eye only, twice a day (6-9 hours apart), for four days and once on the fifth day (total of 9 eye drops treatment for each), both groups will have 2 days of washout, and will be crossed to identical course of treatment with the other ophthalmic formulation. all eye drops treatments will be done on the medical site by one of the study staff unblinded to the treatment. the investigator assessing the ocular signs and the participants will be blinded to study treatment.

Eligibility criteria:
inclusion criteria: 1. male or female aged 20-50 years, inclusive. 2. systemically and ophthalmologically healthy subjects evaluated during the clinical history. 3. best-corrected visual acuity (bcva) 20/40 or better in both eyes. 4. negative fluorescein staining in fluorescein corneal staining (fcs) in both eyes. 5. up to 0.5 conjunctival redness in conjunctival redness without slit lamp, in standardized lighting conditions, in both eyes. 6. iop (\< 22mmhg), in both eyes. 7. no pathology findings in slit-lamp biomicroscopy in both eyes. 8. ability to comply with the requirements of the study and complete the questionnaire and a full sequence of protocol-related evaluations. 9. ability to understand and provide written informed consent. 10. in the judgement of the investigator, the participant can safely perform study activity. exclusion criteria: 1. have chronic systemic disease of any form known. 2. in the case of women: be pregnant, breastfeeding or planning to become pregnant within the study period or women without a history of hysterectomy, oophorectomy, who do not ensure a hormonal contraceptive method or intrauterine device during the study period. 3. be a user of topical ophthalmic products of any kind. 4. being a chronic drug user. 5. be a user of contact lenses. 6. have a history of any type of eye surgery. 7. participating in clinical research studies 90 days prior to inclusion in the present study. 8. in the judgement of the investigator, any condition that could interfere with the intent of the study or would make participation not in the best interest of the participant.
glucose clamp study to prove hypo- and hyperglycemic episodes using a non-invasive glucose monitoring device

Conditions: Diabetes Mellitus

Summary: continuous monitoring of the skin tissue glucose concentration on two different study days using glucose sensors that work on the principle of impedance spectroscopy, with systematic alteration of the blood glucose concentration using the glucose clamp technique in healthy subjects and subjects with type 1 diabetes. simultaneous determination of electrolyte concentrations in the blood by taking frequent blood samples.

a completely non-invasive continuous glucose monitoring device is considered as a major target of glucose sensor development. the aim of this study is to evaluate the performance of a non-invasive glucose sensor (wristwatch) under controlled conditions (glucose clamp) at hyperglycemia (study day 1) and at hypoglycemia (study day 2). measurements of the non-invasive glucose monitoring device are compared to those obtained from a minimally invasive glucose monitoring device (glucoday, microdialysis principle). in addition, changes in blood electrolyte concentrations as well as their impact on the measurements of the non-invasive glucose sensor are evaluated.

Eligibility criteria:
inclusion criteria: healthy male and female volunteers: * written informed consent * aged between 18 and 40 years * body mass index between 18 and 28 kg/m² * haemoglobin \> 13 g% male and female patients with type 1 diabetes: * known type 1 diabetes, first manifestation 6 months to 15 years before the start of the study * hba1c \<= 9% * written informed consent * aged between 18 and 40 years * body mass index between 18 and 28 kg/m² * haemoglobin \> 13 g% exclusion criteria: * uncontrolled arterial hypertension (diastolic blood pressure \>100 mmhg and/or systolic blood pressure \> 180 mmhg) * for women, pregnancy or breast-feeding or, for sexually active women of child-bearing age, the use of contraceptive methods considered to be safe (oral contraceptives, iud, implanted or injected contraceptives, diaphragms, or surgical sterilisation of the patient or her partner) * deviations in the lab values (excluding hba1c), as judged by the investigator to be clinically significant, in particular an increase in transaminases to a level that is two and a half times higher than the upper normal value and a creatinine value that is above the normal range * severe acute diseases, as judged by the investigator * severe chronic disease, as judged by the investigator * history of macrovascular illnesses such as pavk, myocardial infarction * known microvascular (diabetic) complications (other than diabetic background retinopathy) * positive serology for hepatitis b, hepatitis c or hiv * blood donation within 3 months prior to the start of the study and intention of donating blood within 3 months after the end of the study

Keywords: diabetes
the effect of digital rehabilitation system with wearable multi-imu (inertial measurement unit) sensors on upper limb functions in children with brain injury

Conditions: Cerebral Palsy; Children With Brain Injury

Summary: this study was designed to establish the clinical evidence for effect of video-game based rehabilitation therapy system using imu sensors as a game interface, newly-developed in korea, on upper limb function of children with cerebral palsy. first, the investigators would compare the effect of video-game based rehabilitation therapy to conventional occupational therapy.

* purpose: to elucidate the effect of video-game based rehabilitation therapy system on upper limb function of children with cerebral palsy compared to conventional occupational therapy * subjects: total 30 children with cerebral palsy whose upper limb functions are impaired (all 30 children will receive the conventional occupational therapy, but 15 of these children will receive the additional video-game based rehabilitation therapy) * intervention: 4 weeks of therapy (6 days per week) * studies: functional mri, computerized motion analysis, upper limb functional assessment (muul, ulprs), adl evaluation, cognitive evaluation * evaluation plan: 1) pre-intervention, 2) post-4 weeks of intervention, 3) 8 weeks after end of intervention

Eligibility criteria:
inclusion criteria: * macs (manual ability classification system) level i, ii, iii, iv * patients without cognitive impairment who are able to comply with protocol-required procedure * male or female, 4 to 18 years exclusion criteria: * patients with cognitive impairment who are unable to comply with protocol-required procedure * patients with significant visual impairment * patients with presence or history of musculoskeletal anomaly who are unable to apply device

Keywords: upper limb function multi-imu (inertial measurement unit) sensors melbourne assessment of unilateral upper limb function (muul-2)
epidemiological study on the safety of aspirin in the health improvement network (thin)

Conditions: Secondary Prevention; Stroke; Ischemic Heart Disease; Coronary Heart Disease

Summary: to investigate the risk of major bleeding (including gastrointestinal and intracranial bleeding episodes) among new users of low-dose acetylsalicylic acid (asa) in clinical practice

these will be based on population-based cohorts using data from a primary care database in the uk: the health improvement network (thin) and will serve to make a clinically meaningful benefit-risk assessment regarding major bleeding consequences of asa exposure in general population.

Eligibility criteria:
inclusion criteria: * aged 40-84 years * enrolled with the primary care physician (pcp) for at least 2 years, * to have a history of computerized prescriptions for at least 1 year prior * to have at least one encounter/visit recorded in the last three years exclusion criteria: * to be exposed to low dose asa before entering in the study * having a diagnosis of cancer before entering in the study * having a diagnosis of alcohol abuse before entering in the study * having a diagnosis of coagulopathies before entering in the study * having a diagnosis of esophageal varices before entering in the study * having a diagnosis of chronic liver disease before entering in the study

Keywords: low-dose acetylsalicylic acid, bleeding, the health improvement network (thin), cardiovascular secondary prevention of cardiovascular events
immunothrombosis with septic shock undergoing renal replacement therapy with the oxiris membrane

Conditions: Sepsis

Summary: sepsis remains a global scourge. before the sars-cov-2 pandemic, the world health organization estimated approximately 49 million cases annually, resulting in 11 million deaths. defined by dysregulated host response to infection, sepsis leads to vital organ failure. renal dysfunction affects about half of icu patients, necessitating extracorporeal renal replacement therapy in approximately 10% of cases, alongside coagulation system involvement typified by thrombocytopenia. immunothrombotic phenomena are pivotal in sepsis pathophysiology, activating coagulation and disrupting immune responses. microcirculatory impairment, mediated by neutrophils, monocytes, and platelets, worsens vital organ perfusion. excessive production of neutrophil extracellular traps (nets) is implicated in microcirculatory compromise during sepsis.


Eligibility criteria:
inclusion criteria: * patients aged 18 years and older * admitted to the intensive care unit with septic shock, defined as an increase in the sequential organ failure assessment (sofa) score of at least 2 points due to infection, requiring vasopressor drugs to maintain a mean arterial pressure (map) ≥ 65 mmhg, and a lactate level \> 2 mmol/l (18 mg/dl) despite adequate fluid resuscitation * requiring renal replacement therapy according to consensus indications: * kdigo stage 3 acute kidney injury with oliguria or anuria persisting for more than 72 hours * urea \> 40 mmol/l * plasma potassium \> 5.5 mmol/l despite medical treatment * ph \ 50 mmhg without the possibility of improving alveolar ventilation) * acute pulmonary edema secondary to hydrosaline overload resulting in severe hypoxemia (oxygen flow \> 5 l/min or fio2 \> 50% during mechanical ventilation to maintain sao2 \> 95%) despite diuretic therapy * receiving continuous renal replacement therapy with a high-adsorption membrane (oxiris membrane) or a conventional membrane (hf1400 membrane) exclusion criteria: * known history of constitutional thrombopathy (bernard soulier disease, glanzmann thrombasthenia, gray's syndrome or dense granule disease) * myelodysplastic or myeloproliferative syndrome * autoimmune thrombocytopenic purpura * acute leukemia * hemorrhagic shock * platelet transfusion within 7 days prior to inclusion * antiplatelet therapy with clopidogrel or ticagrelor within 5 days prior to inclusion, prasugrel or dipyridamole within 7 days prior to inclusion * active hiv infection or hepatitis b or c * pregnant woman * not affiliated to a social security system or not benefiting from such a system

Keywords: intensive care immunothrombosis nets neutrophils platelets
relative bioavailability study of ropinirole implants in parkinson's patients on l-dopa switched from oral ropinirole

Conditions: Parkinson Disease

Summary: subjects stable on l-dopa and oral ropinirole will have their ropinirole replaced with the ropinirole implant(s). the ropinirole implant was designed using the proneura™ implant technology where the implant is inserted under the skin. this study will measure how much ropinirole is released in the blood during 12 weeks of ropinirole implant treatment, and evaluate the side effects of this new formulation.


Eligibility criteria:
key inclusion criteria: * voluntarily provided informed consent * meet diagnostic criteria for idiopathic parkinson's disease * on l-dopa and oral ropinirole * if female of child-bearing potential, willing to practice contraception from time of informed consent to follow-up visit key exclusion criteria: * pregnant, breastfeeding, or planning to become pregnant * active epilepsy within the past year * severe dementia or cognitive impairment * donated or lost \> 400 ml of blood within 1 month prior to screening * history of alcohol or substance use disorder within the prior 12 months * recent episodes of moderate to severe dizziness or syncope * definite or suspected hypersensitivity to ropinirole or ethylene vinyl acetate * used any other investigational drug within 60 days or 5 half-lives prior to screening, or plan to take any such drug any time during the study

Keywords: parkinson disease dyskinesia ropinirole implant proneura movement disorders dopamine agonist extended-release parkinsonian disorders brain diseases central nervous system diseases neurodegenerative diseases antiparkinson agents anti-dyskinesia agents dopamine agents neurotransmitter agents requip subdermal
efficacy of digital game addiction awareness training for parent

Conditions: Game Addiction, Video

Summary: the study will be conducted with the randomized controlled experimental method. the purpose of this research is to determine the effect of digital game addiction awareness training given to parents of 6th-grade secondary school students on their parents' awareness levels of digital game addiction. parents will be randomly assigned to groups by lottery method. after the randomization parents of students in the intervention group will be given 'digital game addiction awareness training'. the digital game addiction awareness level of all parents will be determined with the 'digital game addiction awareness scale' before and 3 months after the training. parents in the control group will not be educated. the digital game addiction awareness level of the parents in the control group will be determined with the 'digital game addiction awareness scale' when they are included in the research and 3 months later.

the use of technological devices such as computers, tablets and smartphones is increasing day by day all over the world. with the widespread use of these high-tech devices and the internet in the last 20 years, digital games have become popular as a leisure activity, especially among children and adolescents. although digital games provide cognitive, social and emotional benefits such as improving hand-eye coordination, three-dimensional thinking, coping with stress, increasing decision-making speed and facilitating learning, excessive digital gaming can lead to psychosocial and medical problems. one of the most important problems that may develop as a result of uncontrolled use of online and offline games is digital game addiction. considering the addiction of digital games, it is very important to raise awareness and awareness of both children and their parents in order to protect children from the risks of digital games and to ensure that they play the games they play in a controlled manner. one of the important methods of raising awareness is to provide training to individuals on the subject for which awareness is desired. in this regard, this research was planned to examine the effect of digital game addiction awareness training on creating and increasing awareness of digital game addiction in the parents of secondary school students.

Eligibility criteria:
inclusion criteria: * being between the ages of 18 and 43, * no auditory, visual, or mental problems that would affect communication * speaking and understanding turkish at native level exclusion criteria: * being younger than 18 years old and older than 43 years old, * having auditory, visual, or mental problems that would affect communication * not speaking and understanding turkish at native level

Keywords: digital game addiction school parent
human immunodeficiency virus (hiv), arterial dysfunction, lipids, lovaza (halo) trial

Conditions: Cardiovascular Disease; HIV Infection

Summary: the purpose of this study is to determine whether fish oil supplementation with lovaza, formally known as omacor will result in a significant reduction in serum triglyceride (tg), an increase in high density lipoproteins(hdl), and an improvement of endothelial dysfunction.

this is a randomized, double blind, placebo controlled, cross-over, clinical trial to determine the effect of fish oil supplementation with lovaza® on triglyceride levels in hiv-infected subjects on haart with elevated serum triglycerides. the sample size is 40 subjects. the total duration of the study is 28 weeks, with 12-week treatment periods separated by a 4-week washout. this study will be conducted at the clinical research center at tufts medical center.

Eligibility criteria:
inclusion criteria: * hiv-infected men and women at least 18 years of age * on stable haart for previous three months and without anticipated changes in their haart regimen throughout the duration of the study * fasting triglycerides \> 150 mg/dl and \< 1,500 mg/dl * participants may be on lipid lowering therapy; if on lipid lowering therapy, therapy must be stable for 8 weeks and cannot be changes during the course of the study * participants may be on beta blockers (e.g., atenolol, metoprolol, propranolol), estrogens (e.g.,estinyl;estrace;estraderm) and thiazides (water pills), however therapy with these agents must be stable for 8 weeks before starting the study and cannot be altered while on the study unless deemed medically necessary by the participant's medical provider and approved by dr. wanke * female participants of reproductive age must not be pregnant (negative test) or lactating at screening and throughout the trial and agree to use 2 methods of barrier contraception for the course of the trial and 2 months after the trial unless they are surgically sterilized (tubal ligation or hysterectomy), or post-menopausal with no menses for \> 1 year * ability to provide consent exclusion criteria: * plasma hiv-1 rna \> 10,000 * previous history of atherosclerotic disease or diabetes mellitus * change in haart regimen over three months prior to study entry * change in lipid lowering therapy within 2 months * on chronic anticoagulants such as heparin or coumadin * on fish oil, omega 3 supplements, or omacor currently or during the past month

Keywords: hiv cardiovascular risk atherogenic lipid profile brachial artery reactivity omega three fatty acids